Various scoring systems evaluating histologic features of chronic hepatitis C treated with interferon

被引:11
作者
Ikawa, H
Hayashi, Y
Ninomiya, T
Yano, Y
Nakaji, M
Nagano, H
Seo, Y
Kumon, Y
Yoon, S
Kasuga, M
Itoh, H
Ohbayashi, C
机构
[1] Kobe Univ, Sch Med, Kobe Univ Hosp, Dept Internal Med 2,Dept Pathol 1, Kobe, Hyogo 650, Japan
[2] Kobe Univ, Sch Med, Kobe Univ Hosp, Div Surg Pathol, Kobe, Hyogo 650, Japan
关键词
scoring system; histology; chronic hepatitis C; interferon therapy;
D O I
10.1053/hupa.2001.27108
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Various scoring systems for chronic hepatitis have been proposed, however, there is no standard scoring system for studies of interferon (IFN) therapy in patients with chronic hepatitis C. The aims of this study were to determine the most useful system reflecting histologic changes in biopsy specimens from complete responders and predicting the efficacy of IFN therapy. Patients with chronic hepatitis C were administered IFN-alpha for 6 months. Forty-six patients were included in this study and categorized as complete responders (n = 15), partial responders (n = 24), and nonresponders (n = 7) according to viral and biochemical responses to the therapy. Biopsy specimens obtained from each patient before and after treatment were evaluated under 3 different systems: Histological Activity Index (HAI), modified HAI, and Scheuer classification. Complete responders showed considerable improvement in both grade and stage on the modified FLU and Scheuer classifications. On the HAI, a considerable improvement was observed in grade but not in stage. No significant change was observed in partial responders or nonresponders on any system. Prediction of complete response was not possible under any system, but the pretreatment score reflecting piecemeal necrosis on any 1 of the 3 classifications and the fibrosis score on Scheuer classification were predictors of nonresponse. The modified HAI system and Scheuer classification were amply useful in evaluating histologic changes in complete responders. Scores higher than 4 of the categories reflecting piecemeal necrosis on any system and fibrosis scores of 3 or 4 on Scheuer classification predicted nonresponse to IFN therapy. Copyright (C) 2001 by W.B. Saunders Company.
引用
收藏
页码:910 / 917
页数:8
相关论文
共 17 条
[11]   Prognosis of chronic hepatitis C:: Results of a large, prospective cohort study [J].
Niederau, C ;
Lange, S ;
Heintges, T ;
Erhardt, A ;
Buschkamp, M ;
Hürter, D ;
Nawrocki, M ;
Kruska, L ;
Hensel, F ;
Petry, W ;
Häussinger, D .
HEPATOLOGY, 1998, 28 (06) :1687-1695
[12]   Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients [J].
Okanoue, T ;
Itoh, Y ;
Minami, M ;
Sakamoto, S ;
Yasui, K ;
Sakamoto, M ;
Nishioji, K ;
Murakami, Y ;
Kashima, K .
JOURNAL OF HEPATOLOGY, 1999, 30 (04) :653-659
[13]   CLASSIFICATION OF CHRONIC VIRAL-HEPATITIS - A NEED FOR REASSESSMENT [J].
SCHEUER, PJ .
JOURNAL OF HEPATOLOGY, 1991, 13 (03) :372-374
[14]  
Shindo M, 1999, CANCER, V85, P1943, DOI 10.1002/(SICI)1097-0142(19990501)85:9<1943::AID-CNCR10>3.0.CO
[15]  
2-F
[16]   Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan [J].
Yoshida, H ;
Shiratori, Y ;
Moriyama, M ;
Arakawa, Y ;
Ide, T ;
Sata, M ;
Inoue, O ;
Yano, M ;
Tanaka, M ;
Fujiyama, S ;
Nishiguchi, S ;
Kuroki, T ;
Imazeki, F ;
Yokosuka, O ;
Kinoyama, S ;
Yamada, G ;
Omata, M .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (03) :174-+
[17]  
ZENIYA M, 2000, J GASTROENTEROL H SE, V15, P117